These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 20889925)

  • 1. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.
    Lamers CH; Willemsen R; van Elzakker P; van Steenbergen-Langeveld S; Broertjes M; Oosterwijk-Wakka J; Oosterwijk E; Sleijfer S; Debets R; Gratama JW
    Blood; 2011 Jan; 117(1):72-82. PubMed ID: 20889925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell activation upon exposure to patient-derived tumor tissue: a functional assay to select patients for adoptive T cell therapy.
    Schroten C; Kraaij R; Veldhoven JL; Berrevoets CA; den Bakker MA; Ma Q; Sadelain M; Bangma CH; Willemsen RA; Debets R
    J Immunol Methods; 2010 Jul; 359(1-2):11-20. PubMed ID: 20460126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells.
    Lamers CH; van Elzakker P; van Steenbergen SC; Luider BA; Groot C; van Krimpen BA; Vulto A; Sleijfer S; Debets R; Gratama JW
    Cytotherapy; 2013 May; 15(5):620-6. PubMed ID: 23388583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
    Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
    Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness.
    Lamers CH; van Steenbergen-Langeveld S; van Brakel M; Groot-van Ruijven CM; van Elzakker PM; van Krimpen B; Sleijfer S; Debets R
    Hum Gene Ther Methods; 2014 Dec; 25(6):345-57. PubMed ID: 25423330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.
    Lamers CH; Sleijfer S; Vulto AG; Kruit WH; Kliffen M; Debets R; Gratama JW; Stoter G; Oosterwijk E
    J Clin Oncol; 2006 May; 24(13):e20-2. PubMed ID: 16648493
    [No Abstract]   [Full Text] [Related]  

  • 7. Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
    Lamers CH; van Elzakker P; Langeveld SC; Sleijfer S; Gratama JW
    Cytotherapy; 2006; 8(6):542-53. PubMed ID: 17148030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
    Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
    Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
    Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
    J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells.
    de Campos NSP; de Oliveira Beserra A; Pereira PHB; Chaves AS; Fonseca FLA; da Silva Medina T; Dos Santos TG; Wang Y; Marasco WA; Suarez ER
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabozantinib enhances CAIX specific CAR-T cells against renal cancer by improving effector functions and augmenting tumor immune microenvironment.
    Li Q; Yang L; Li S; Zhao W; Xue Y; Lu Z; Tang J; Gao X; Zheng J; Zhang Q; Sun S
    Biochem Biophys Res Commun; 2024 Nov; 734():150781. PubMed ID: 39368372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.
    Lamers CH; Sleijfer S; van Steenbergen S; van Elzakker P; van Krimpen B; Groot C; Vulto A; den Bakker M; Oosterwijk E; Debets R; Gratama JW
    Mol Ther; 2013 Apr; 21(4):904-12. PubMed ID: 23423337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma IFN-γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells.
    Klaver Y; van Steenbergen SCL; Sleijfer S; Debets R; Lamers CHJ
    Clin Immunol; 2016 Aug; 169():107-113. PubMed ID: 27377533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects.
    Wang Y; Buck A; Piel B; Zerefa L; Murugan N; Coherd CD; Miklosi AG; Johal H; Bastos RN; Huang K; Ficial M; Laimon YN; Signoretti S; Zhong Z; Hoang SM; Kastrunes GM; Grimaud M; Fayed A; Yuan HC; Nguyen QD; Thai T; Ivanova EV; Paweletz CP; Wu MR; Choueiri TK; Wee JO; Freeman GJ; Barbie DA; Marasco WA
    Mol Cancer; 2024 Mar; 23(1):56. PubMed ID: 38491381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview.
    Lamers CH; Klaver Y; Gratama JW; Sleijfer S; Debets R
    Biochem Soc Trans; 2016 Jun; 44(3):951-9. PubMed ID: 27284065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells.
    Bleumer I; Tiemessen DM; Oosterwijk-Wakka JC; Völler MC; De Weijer K; Mulders PF; Oosterwijk E
    J Immunother; 2007 Jan; 30(1):116-22. PubMed ID: 17198090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation.
    Burns WR; Zheng Z; Rosenberg SA; Morgan RA
    Blood; 2009 Oct; 114(14):2888-99. PubMed ID: 19589923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models.
    Birkhäuser FD; Koya RC; Neufeld C; Rampersaud EN; Lu X; Micewicz ED; Chodon T; Atefi M; Kroeger N; Chandramouli GV; Li G; Said JW; McBride WH; Kabbinavar FF; Ribas A; Pantuck AJ; Belldegrun AS; Riss J
    J Immunother; 2013 Feb; 36(2):102-11. PubMed ID: 23377663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes.
    Weijtens ME; Willemsen RA; Hart EH; Bolhuis RL
    Gene Ther; 1998 Sep; 5(9):1195-203. PubMed ID: 9930320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strong immunogenic potential of a B7 retroviral expression vector: generation of HLA-B7-restricted CTL response against selectable marker genes.
    Jung D; Jaeger E; Cayeux S; Blankenstein T; Hilmes C; Karbach J; Moebius U; Knuth A; Huber C; Seliger B
    Hum Gene Ther; 1998 Jan; 9(1):53-62. PubMed ID: 9458242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.